• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration

    9/23/25 7:07:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and their patients

    SECAUCUS, N.J., Sept. 23, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testing in the United States.

    questhealth.com logo (PRNewsfoto/Quest Diagnostics)

    Epic will work with Quest to deliver a suite of technologies and services to act as the foundation for Project Nova, Quest's multi-year initiative to simplify and enhance several of the company's customer-facing processes to improve experiences, quality and productivity for patients and providers--regardless of the electronic health record (EHR) platform they use. The implementation will be unique with the breadth of Epic's Diagnostic Enterprise system for laboratories--which includes Aura, Beaker Laboratory, Care Everywhere, MyChart, and Resolute Professional Billing & Claims--to be scaled across Quest's national laboratory operation.

    "Our collaboration with Epic will raise the bar on what health systems, providers and their patients can expect from their lab experience," said Jim Davis, CEO, Chairman and President, Quest Diagnostics. "Aligning Epic's leading healthcare technologies across our network will help us to optimize insights and experiences for customers and patients while also driving productivity across our enterprise."

    "Together, Epic and Quest will make testing easier to navigate for patients while reducing friction for providers and health systems," Sumit Rana, President at Epic, said. "From creation of a single comprehensive test list to a better patient experience with MyChart and more, this is an opportunity to transform the healthcare experience at a national scale." 

    The implementation will focus on:

    • Consolidating technologies to improve operational agility, efficiency and quality
    • Streamlining systems ranging from account onboarding, lab ordering and results reporting to patient appointment scheduling, billing and customer service, for greater convenience and ease-of-use for customers
    • Enhancing the patient experience through solutions including MyChart to foster greater transparency in health plan reimbursement and simplify appointment scheduling at Quest's 2,000 patient service centers in the U.S.

    Expected customer benefits include faster, more convenient services, access to deeper health and other insights, and faster turnaround times for some testing services. By simplifying systems, the Epic implementation may also allow for faster installment of new innovations, including AI and automation, as new technologies become available.

    "The best healthcare companies create innovative solutions that are convenient to access, easy to use and personalized," said Murali Balakumar, Senior Vice President and Chief Information and Digital Officer, Quest Diagnostics. "We are focused on delivering these kinds of solutions across our entire portfolio, leveraging Epic as a foundational technology collaborator, so patients and providers can seamlessly engage with us for their labs and other health insights."

    A cross-organization team experienced in large-scale implementations will lead a multi-year phased implementation that prioritizes a seamless transition for health systems, hospitals and other providers.

    About Quest Diagnostics

    Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

    Forward Looking Statements

    The statements in this press release which are not historical facts may be forward-looking statements.  Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-improve-laboratory-testing-experience-with-industry-first-epic-collaboration-302563549.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Davis J. E. exercised 55,093 shares at a strike of $95.80 and sold $10,589,760 worth of shares (55,093 units at $192.22) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    11/28/25 4:30:50 PM ET
    $DGX
    Medical Specialities
    Health Care

    Director Gregg Vicky B sold $239,700 worth of shares (1,250 units at $191.76), decreasing direct ownership by 7% to 17,037 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    11/28/25 4:30:31 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP & Chief Commercial Officer Delaney Mark E exercised 7,946 shares at a strike of $144.46 and sold $1,488,683 worth of shares (7,946 units at $187.35) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    11/20/25 4:28:10 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

    New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes.

    2/2/26 8:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year

    SECAUCUS, N.J., Jan. 21, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that it has been named to the Fortune® magazine 2026 World's Most Admired Companies™ list, for the 12th consecutive year. "Quest's recognition as one of the world's most admired companies reflects the commitment of our 55,000 colleagues to living our purpose every day: working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "We are proud to again be named among this elite list

    1/21/26 2:35:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    SEC Filings

    View All

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    1/12/26 4:37:53 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    10/21/25 6:50:12 AM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Quest Diagnostics Incorporated

    10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    10/21/25 6:31:10 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

    SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast

    1/8/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Nov. 11, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record of Quest Diagnostics common stock on January 13, 2026. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to t

    11/11/25 4:22:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

    Third quarter revenues of $2.82 billion, up 13.1% from 2024Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66; and adjusted diluted EPS is expected to be between $9.76 and $9.84SECAUCUS, N.J., Oct. 21, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.

    10/21/25 6:45:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care